Meetings and publications
>> VHPB meetings

Viral Hepatitis  Prevention  Board

Budapest, Hungary, March 18-19, 2009

Identification and management of persons with chronic viral hepatitis in Europe

Thursday, March 18, 2010

Session 1  Introduction
Chair:  David Goldberg, Mark Kane

• Welcome and opening
• Introduction of the participants
• Introduction of the VHPB:    717 kB (.pdf) prepared by  Mark Kane
• Objectives of the meeting:
  • To take stock of the current screening of chronic diseases and lessons learnt;
  • To apply the screening criteria ( the Wilson and Jungner criteria) on the identification of persons with chronic hepatitis;
  • To report on HTA (health technology assessment) of such identification programmes;
  • To learn how screening and the management of the identified persons  can reduce the morbidity and mortality of chronic viral hepatitis;
  • To discuss if the potential benefits of identifying chronic viral hepatitis and preventing the development of the health problem outweigh the cost and potential harm associated with the screening process;
  • List the conditions required for the successful implementation;
  • Discuss strength and weaknesses of screening as well as other public health and social aspects or consequences;
  • Evaluate the impact of a diagnosis on individual well being.
• Review of the meeting programme
• Pre-meeting document   212 KB (.pdf)

Session 2 Screening for persons with underlying chronic disease

09.00 – 09.30
Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.  518Kb (.pdf)
Anne Andermann

Lessons learnt from other screening programmes

09.30 – 09.50
HIV   345Kb (.pdf)
Caroline Semaille-Safar

09.30 – 09.50
Screening for Chronic Kidney disease: Where does Europe go?.  955Kb (.pdf)
Paul E de jong

10.10 – 10.20 Discussion

10.20 – 10.40 Coffee Break

Chair: John Ward, Helθne Norder

10.40 – 11.00
Results of a literature study on hepatitis screening in Europe
Mika Salminen (ECDC)

11.00 – 11.20
Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection    426Kb (.pdf)
Gaby Sroczynski

11.20 – 11.30 Discussion

Session 3 Global burden of disease

11.30 – 11.50
Burden of disease of viral hepatitis    776Kb (.pdf)
Steven Wiersma (WHO)

11.50 – 12.10
Surveillance data and case definitions to define the burden of disease in Europe    545Kb (.pdf)
David Mercer (WHO-Europe)

12.10 – 12.20 Discussion

12.20 – 13.40 Lunch

Session 4  Ongoing activities to raise awereness and gather information about chronic viral hepatitis and organizations' vision on screening
Chair: Johannes Hallauer, Daniel Lavanchy

13.40 – 13.55
Institute of Medicine (IOM)   820Kb (.pdf)
Brian Mc Mahon

13.55 – 14.10
ECDC
Marita van de Laar 

14.10 –14.25
EASL 1,7Mb (.pdf)
Heiner Wedemeyer  

14.25 – 14.40
ELPA  743Kb (.pdf)
Nadine Piorkowsky

14.40 – 14.55
SOTA  431Kb (.pdf)
Nadine Piorkowsky

14.55 – 15.10
WHO  420Kb (.pdf)
Steven Wiersma

15.10 – 15.25 Discussion

15.25 – 15.45 Coffee Break

Session 5  Management of identified persons with chronic viral hepatitis
Chair: Daniel Shouval, Marinho Rui Tato

15.45 – 16.05
Update on treatment for hepatitis B and C. 1.3Mb (.pdf)
Heiner Wedemeyer

16.05 –16.25
Recommendations regarding viral hepatitis care and treatment. Whome to treat - When to treat?   868Kb (.pdf)
Geoffrey Dusheiko 

16.25 – 16.45
Need for long term evaluation of therapy     469Kb (.pdf)
Solko Schalm

16.45 – 17.05
Economics of chronic hepatitis B and hepatitis C   487Kb (.pdf)
John Wong

17.05 – 17.20 Discussion

17.20              End of the Day

Friday, March 19, 2010

Session 6  Country Sessions
Chair: Steven Wiersma, Vana Papaevangelou

09.00 – 09.20
Migrant screening: challenges and options.   59Kb (.pdf)
Rowan Cody

09.20 – 09.40
Alaska.   623Kb (pdf)
Brian McMahon

09.40 – 10.00
Belgium   200Kb (.pdf)
Isabelle Colle (BASL)

10.00 – 10.20
France    793Kb (.pdf)
Francoise Roudot-Thoraval

10.20 – 10.40
Italy    585Kb (.pdf)
Daniele Prati

10.40 – 11.00 Coffee break

Chair: Hans Blystad, Alessandro Zanetti

11.00 – 11.20
Scotland  303Kb (.pdf)
David Goldberg

11.20 – 11.40
UK  119Kb (.pdf)
William Irving

11.40 – 12.00
USA  908Kb (.pdf)
Geoff Beckett (CDC)

12.00 – 12.20
Russia  463 Kb (.pdf)
Vladimir Chulanov

12.20 – 12.40
the Netherlands 197 Kb (.pdf)
Irene Veldhuijzen

12.40 – 12.50 Discussion

12.50 – 14.15 Lunch

Session 7 Conclusions of the meeting
Chair:  Pierre Van Damme, Francoise Roudot Thorval

14.15 – 15.15
Presentation of the VHPB meeting conclusions   86Kb (.pdf)
D. FitzSimons
 
15.15         End of the meeting